SPINK1 and cancer: As the response of the TME to anticancer agents can be molecularly identified by monitoring the circulating SASP factors in patient blood, SPINK1 represents both a biomarker that merits further investigation to establish its potential as a standard of cancer surveillance and a target to develop humanized antibodies for clinical trials.